Skip to content

Impact of Covid-19 on Rhinovirus Epidemic

Impact of Covid-19 Pandemic on the Epidemiology of Rhinovirus

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05348707
Acronym
IPCoRV
Enrollment
400
Registered
2022-04-27
Start date
2022-05-31
Completion date
2023-05-31
Last updated
2022-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhinovirus

Keywords

Rhinovirus epidemic, SARS-CoV2/Rhinovirus interaction, Children, Non-pharmacological-interventions, Bronchiolitis, Asthma, Pneumonia, Fever, Meningitis, Rhinovirus infection in children less than 1 years of age

Brief summary

Rhinovirus (RV) has long been known as the main etiological agent of common colds among children and adults. Indeed, RV is involved in more than 50% of upper respiratory tract infections (URTIs), mostly characterized by nasal congestion, rhinorrhea, sore throat and cough. RV can also cause mild to severe lower respiratory tract infections (LRTIs) such as acute bronchiolitis, pneumonia and exacerbations of underlying chronic lung diseases. RV circulates worldwide, especially in temperate climate zones (i.e. many areas of the USA and Europe) and is responsible for annual outbreaks from early fall to the end of spring. The covid-19 pandemic in 2020 seemed to interfere with the usual seasonal epidemics. For example, the winter Respiratory Syncytial Virus (RSV) epidemic in Lyon, France, was delayed for several months and reduced by half in terms of incidence of hospitalization cases. This can be explained by the widespread deployment of barrier gestures and social distancing measures, known as non pharmacological interventions (NPI). However, the Covid-19 pandemic doesn't seem to have the same reducing impact on Rhinovirus epidemic. A better understanding of viral interactions and factors influencing RV epidemiology as well as the identification of populations at greater risk are required to improve preventive strategies and reduce the burden of Rhinovirus.

Interventions

OTHERepidemiology

To review medical records to describe diagnosis and severity of the disease.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 1 Years
Healthy volunteers
No

Inclusion criteria

* \- Child hospitalized at the Hopital Femme Mere Enfant , Lyon, France * Positive rhinovirus-PCR

Exclusion criteria

* \- parent's refusal to participate

Design outcomes

Primary

MeasureTime frameDescription
Evolution of the number of children hospitalized for a Rhinovirus-infection in the period of pre Covid-19 pandemic.From one year before the SARS-CoV-2 pandemic until the beginning of the SARS-CoV-2 pandemicDescription of number of clinical picture cases for pre-SARS-CoV-2 pandemic year.
Evolution of the number of children hospitalized for a Rhinovirus-infection in the period of per-Covid-19 pandemic.From the beginning of the SARS-CoV-2 pandemic until one year latterDescription of number of clinical picture cases for per-SARS-CoV-2 pandemic year.

Contacts

Primary ContactDominique PLOIN, MD
dominique.ploin@chu-lyon.fr: 04 27 85 56 42
Backup ContactJean Sebastien CASALEGNO, MD
jean-sebastien.casalegno@chu-lyon.fr04 72 07 10 23

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026